Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 4/2013

01.12.2013 | short review

Brentuximab vedotin, a highly active ADC as a new therapeutic option for CD30+ lymphomas

verfasst von: Sofia Stamatopoulou, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Hodgkin lymphoma (HL) and systemic anaplastic large-cell lymphoma (sALCL) are lymphoproliferative types of cancer. The chemotherapy regimens of HL such as ABVD (doxorubicin, bleomycin, vinblastine, decarbazine) and BEACOPP (bleomycin, etoposide, doxorubicin, cyclophospamide, vincristine, procarbazine, prednisone) have made the most curable malignancies. Unfortunately, 15–30 % of these patients will relapse again and treatment options become limited, so we need to develop new therapeutic approaches. ALCL has unique molecular and immunohistochemical features that make it an ideal model for developing targeted therapies. Antibody-drug conjugates (ADCs), consist of an antibody, a cytotoxic agent, a stable linker and allow delivery of high doses of cytotoxic drugs to cancer cells while sparing normal tissues exposure to high systemic concentration of the cytotoxic agent. Brentuximab vedotin is an anti-CD30 monoclonal antibody conjugate with a potent microtubule inhibitor monomethyl auristatin E. In August 2011, the United States Food and Drug Administration (FDA) approved brentuximab vedotin to treat HL after failure of autologous stem cell transplantation or at least two combination chemotheraphy regimens and for sALCL after failure of at least one prior multidrug chemotherapy regimen. With this approval, brentuximab vedotin is a promising ADC directed against the CD30 antigen.
Literatur
3.
Zurück zum Zitat Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62 (abstr 10–29). Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62 (abstr 10–29).
4.
Zurück zum Zitat Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma not otherwise specified: report from the international peripheral T-Cell Lymphoma Project. Blood. 2008;111 (abstr 5496–504). Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma not otherwise specified: report from the international peripheral T-Cell Lymphoma Project. Blood. 2008;111 (abstr 5496–504).
6.
Zurück zum Zitat Horning S, Fanale M, deVos S, et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort (abstract). Ann Oncol. 2008;19 (abstr iv120–1). Horning S, Fanale M, deVos S, et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort (abstract). Ann Oncol. 2008;19 (abstr iv120–1).
7.
Zurück zum Zitat Moskowitz A, Perales M, Kewalramani T, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol. 2009;146 (abstr 158–63). Moskowitz A, Perales M, Kewalramani T, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol. 2009;146 (abstr 158–63).
8.
Zurück zum Zitat Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol. 2010;14 (abstr 529–5537). Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol. 2010;14 (abstr 529–5537).
9.
Zurück zum Zitat Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonical antibodies. Bioconjug Chem. 2010;21:(abstr 5–13). Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonical antibodies. Bioconjug Chem. 2010;21:(abstr 5–13).
10.
Zurück zum Zitat Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, et al. Production of monoclonal antibody specific for Hodgkin and Sternberg–Reed cells. Nature. 1982;299:(abstr 65–7). Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, et al. Production of monoclonal antibody specific for Hodgkin and Sternberg–Reed cells. Nature. 1982;299:(abstr 65–7).
11.
Zurück zum Zitat Younes A. CD30-targeted antibody therapy. Curr Opin Oncol. 2011;23:(abstr 587–93). Younes A. CD30-targeted antibody therapy. Curr Opin Oncol. 2011;23:(abstr 587–93).
12.
Zurück zum Zitat Katz J, Janik JE, Younes A. Brentuximab vedotin. Cancer Res. 2011;17:(abstr 6428–36). Katz J, Janik JE, Younes A. Brentuximab vedotin. Cancer Res. 2011;17:(abstr 6428–36).
13.
Zurück zum Zitat Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vc-MMAE, an anti-CD30 monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102:(abstr 1458–65). Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vc-MMAE, an anti-CD30 monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102:(abstr 1458–65).
14.
Zurück zum Zitat Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30 auristatin conjugates. J Biol Chem. 2006;281:(abstr 10540–7). Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30 auristatin conjugates. J Biol Chem. 2006;281:(abstr 10540–7).
15.
Zurück zum Zitat De Dlaro RA,McGinn, Kwitkowski V, et al. U.S. Food and Drug Administation approval summary: brentuximab vedotin for the treatment of relapsed Hodgin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res. 2012;18(21):(abstr 5845–9). De Dlaro RA,McGinn, Kwitkowski V, et al. U.S. Food and Drug Administation approval summary: brentuximab vedotin for the treatment of relapsed Hodgin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res. 2012;18(21):(abstr 5845–9).
16.
Zurück zum Zitat Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:(abstr 2183–9). Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:(abstr 2183–9).
17.
Zurück zum Zitat Chen RW, Gopal AK, Smith SE, et al. Long-term survival analysis of an ongoing phase II trial of brentuximab vedotin in patients with relapsed or refractory Hodgin lymphoma. Blood. 2012;120:(abstr 3689). Chen RW, Gopal AK, Smith SE, et al. Long-term survival analysis of an ongoing phase II trial of brentuximab vedotin in patients with relapsed or refractory Hodgin lymphoma. Blood. 2012;120:(abstr 3689).
18.
Zurück zum Zitat Pro B, Advani R, Brice P, et al. Durable remission with brentuximab vedotin: update results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma. J Clin Oncol. 2011;29:(abstr 8032). Pro B, Advani R, Brice P, et al. Durable remission with brentuximab vedotin: update results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma. J Clin Oncol. 2011;29:(abstr 8032).
19.
Zurück zum Zitat Clinical Trial.gov. A randomized double-blind placebo-controlled phase III study of brentuximab and best supportive care versus placebo and best supportive care in the treatment of patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant. Asccessed: 26 Feb 2012. Clinical Trial.gov. A randomized double-blind placebo-controlled phase III study of brentuximab and best supportive care versus placebo and best supportive care in the treatment of patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant. Asccessed: 26 Feb 2012.
Metadaten
Titel
Brentuximab vedotin, a highly active ADC as a new therapeutic option for CD30+ lymphomas
verfasst von
Sofia Stamatopoulou, MD
Publikationsdatum
01.12.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0122-8

Weitere Artikel der Ausgabe 4/2013

memo - Magazine of European Medical Oncology 4/2013 Zur Ausgabe